Bioceltix S.A. (WSE:BCX)
Poland · Delayed Price · Currency is PLN 102.80
-3.00 (-2.84%)
Aug 1, 2025, 5:00 PM CET
Bioceltix Company Description
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.
Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses.
The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A.
| Country | Poland |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Lukasz Bzdzion |
Contact Details
Address: Building III Wroclaw, 51-317 Poland | |
| Phone | 48 71 880 8771 |
| Website | bioceltix.com |
Stock Details
| Ticker Symbol | BCX |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLBCLTX00019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lukasz Bzdzion | President of the Management Board |
| Dr. Pawel Wielgus | Member of the Management Board |
| Andrij Wlach | Chief Financial Officer |
| Grzegorz Ostropolski | Chief Operating Officer |
| Dr. Jakub Grzesiak Ph.D. | Technology Director |